海翔药业：2025年半年度净利润约1409万元

Company Performance - Haixiang Pharmaceutical reported a revenue of approximately 925 million yuan for the first half of 2025, representing a year-on-year decrease of 10.94% [1] - The net profit attributable to shareholders of the listed company was approximately 14.09 million yuan, down 63.01% year-on-year [1] - Basic earnings per share were 0.01 yuan, reflecting a year-on-year decrease of 50% [1] Industry Context - The news highlights the competitive landscape in the automotive sector, with nearly 120 brands and 1,600 vehicles participating in the upcoming A-class car exhibition in Southwest China [1] - The event is expected to reshape the market dynamics for new energy vehicles, referred to as the "third pole" in the industry [1]